<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739986</url>
  </required_header>
  <id_info>
    <org_study_id>CNI-1493-CD04</org_study_id>
    <nct_id>NCT00739986</nct_id>
  </id_info>
  <brief_title>Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo</brief_title>
  <acronym>CD04</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the number of days' treatment with semapimod necessary for efficacy, as
      measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to
      severe Crohn's disease (CD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crohn's Disease Activity Index (CDAI) score</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's disease endoscopic index of severity (CDEIS)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of C-reactive protein (CRP)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse events)</measure>
    <time_frame>Days 29 and 57</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semapimod 60 mg IV x 1 day, placebo IV x 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semapimod 60 mg IV x 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator IV x 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semapimod</intervention_name>
    <description>semapimod 60 mg IV x 1 day, placebo x 2 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semapimod</intervention_name>
    <description>Semapimod 60 mg IV x 3 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo IV x 3 days</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women at least 18 years of age.

          2. Baseline Crohn's Disease Activity Index (CDAI) 250-400.

          3. Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis,
             confirmed by radiography and/or endoscopy.

          4. Those of childbearing potential were to use a barrier method (diaphragm or condom) of
             contraception and continue doing so for at least 3 months after last study medication.
             It was recommended that two forms be used.

          5. Patients receiving medications for CD were to be on each medication for at least 8
             weeks prior to screening and on stable doses of each for at least 2 weeks prior to
             screening, with the following exceptions:

               -  those on methotrexate had to be on a stable dose for at least 4 weeks and not be
                  receiving more than 25 mg/wk

               -  those on azathioprine or 6-mercaptopurine on a stable dose for at least 10 weeks

               -  those on steroids had to have been on steroids for at least 2 weeks and on a
                  stable dose for those 2 weeks. They were not to be receiving more than 20 mg/day
                  prednisone or equivalent

               -  those on mesalazine had to have been on for at least 6 weeks and on a stable dose
                  for at least 2 weeks

               -  those on antibiotics for CD had to have been on for at least 2 weeks and on a
                  stable dose for those 2 weeks

          6. Any CD medication which had been discontinued was to have been discontinued at least 4
             weeks prior to screening, with the exception of infliximab, which was to have been
             discontinued at least 8 weeks prior to screening.

          7. The screening laboratory tests were to meet the following criteria:

             Hgb &gt;= 8.5 g/dL (5.3 mmol/L) WBC 3.5-20 x 109/L Neutrophils &gt;= 1.5 x 109/L Platelets
             &gt;= 100 x 109/L ALT (SGPT) &lt;1.5 x the upper limit of normal range Alkaline phosphatase
             &lt;2.5 x the upper limit of normal range Bilirubin &lt;25 mmol/L (1.5 mg/dl) Creatinine
             &lt;110 mol/L (1.2 mg/dl)

          8. Patients were to be able to adhere to the study visit schedule and/or protocol
             requirements.

          9. Patients were to be able to give informed consent and the consent was to be obtained
             prior to any study specific screening procedures.

        Exclusion Criteria:

          1. Treatment with any other experimental therapeutics within the last 4 weeks before
             enrolment.

          2. History of tuberculosis, either clinically or as evidenced by a positive chest x-ray
             (exclusion criterion #8) or PPD.

          3. Patients who had received anti-TNF therapy, such as infliximab, within 8 weeks of
             screening for this study. Patients who had received anti-TNF therapy &gt;8 weeks prior to
             screening were eligible.

          4. Patients with any ostomy, extensive bowel resection (e.g., more than 100cm of small
             bowel, proctocolectomy or colectomy with ileorectal anastomosis). Segmental colectomy
             was permitted.

          5. Patients immediately in need of surgery for active gastrointestinal bleeding,
             peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess
             requiring surgical drainage.

          6. Patients with known severe fixed symptomatic stenosis of the small or large intestine.

          7. Evidence at the time of enrolment of bowel obstruction or history within the preceding
             six months as confirmed by radiography, endoscopy, or surgery.

          8. Patients with a clinically significant abnormality or granulomata or any other
             evidence of primary tuberculosis infection on chest X-ray

          9. Patients with current signs or symptoms of clinically significant hematologic,
             endocrine, pulmonary, cardiac, neurologic or cerebral disease.

         10. Patients with previous diagnosis of, or known, malignancies.

         11. Patients with serious infections, such as hepatitis, HIV, pneumonia or pyelonephritis,
             within 3 months prior to screening.

         12. History of opportunistic infections such as herpes zoster within 2 months prior to
             screening, evidence of active CMV, active Pneumocystis carinii, drug resistant
             atypical mycobacterium.

         13. Patients with stool examination positive for enteric pathogens, pathogenic ova or
             parasites, or Clostridium difficile toxin.

         14. Women who were pregnant or breast-feeding.

         15. A psychiatric, addictive, or any disorder that compromises ability to give truly
             informed consent for participation in this study.

         16. Patients who had received CNI-1493 in the past.

         17. More than three doses of NSAIDs, including aspirin and COX-2 inhibitors, within the
             two weeks prior to start of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daan Hommes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Healthcare Assessment</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology Associates</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asher Kornbluth, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benjamin Franklin University</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinischen Hochschule-Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats Klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Fachpraxis</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Krankenhaus Munchen-Bogenhausen</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Free University (Vrije Universiteit)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2008</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>TNF-alpha</keyword>
  <keyword>IL-6</keyword>
  <keyword>MAP Kinase</keyword>
  <keyword>CNI-1493</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Semapimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

